Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synergy CHC Has UrgentRx Ticket To Enter OTC Market

This article was originally published in The Tan Sheet

Executive Summary

Synergy also acquires Australian brand Flat Tummy Tea. Both deals partly are financed through a $5.5m loan from Knight Therapeutics, a Canadian firm that in January also provided Synergy with a $6m loan to acquire the Focusfactor dietary supplement brand.

You may also be interested in...



Interview: Fugate Attracted By UrgentRx Focus On Branding, Unique Positioning

Ron Fugate sees UrgentRx not only using some of the strongest marketing strategies he’s known for building a successful consumer health care product brand, but also making headway in new areas important to driving sales for new products.

MacuHealth Asserts ‘Rigorous Process’ In Research Supporting Claims, But No Bill Of Health From NAD

“MacuHealth believes challenged claims are thoroughly supported by the multitude of peer reviewed, published scientific studies” but NAD review on Vision Elements challenge finds firm’s research doesn’t support its claims.

FTC's Substantiation Expectations In Consumer Health Claim Guidance Aren’t ‘Out Of Nowhere'

“Choosing which claims to make,” an advertiser “affects the amount of substantiation required. A structure function claim, supports digestive health, may require a different level of substantiation than if you choose to make the claim prevents diarrhea,” says FTC attorney Christine DeLorme.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel